Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 15/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SHBG | P04278 | 2/20 | 0.49 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.49 |
| ▸ | SNCA | P37840 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.48 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8568513 | 0.86 | SRD5A2 (0.45) | SRD5A2SRD5A1 | |
| SCHEMBL8568510 | 0.86 | SRD5A2 (0.45) | SRD5A2SRD5A1 | |
| SCHEMBL8528520 | 0.84 | SRD5A2 (0.59) | SRD5A2SRD5A1 | |
| SCHEMBL8528521 | 0.84 | SRD5A2 (0.59) | SRD5A2SRD5A1 | |
| SCHEMBL8531699 | 0.84 | SRD5A2 (0.54) | SRD5A2SRD5A1 | |
| SCHEMBL8531693 | 0.84 | SRD5A2 (0.54) | SRD5A2SRD5A1 | |
| SCHEMBL8528628 | 0.84 | SRD5A2 (0.60) | SRD5A2SRD5A1 | |
| SCHEMBL8528626 | 0.84 | SRD5A2 (0.60) | SRD5A2SRD5A1 | |
| SCHEMBL9388464 | 0.82 | SRD5A2 (0.44) | SRD5A2SRD5A1 | |
| SCHEMBL3795725 | 0.79 | CYP19A1 (0.42) | CYP19A1LMNASHBGSERPINA6PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105700-A1 | DECAHYDRO-1H-INDENOQUINOLINONE AND DECAHYDRO-3H-CYCLOPENTAPHENANTHRIDINONE CYP17 INHIBITORS | LEAD THERAPEUTICS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105700-A1 | DECAHYDRO-1H-INDENOQUINOLINONE AND DECAHYDRO-3H-CYCLOPENTAPHENANTHRIDINONE CYP17 INHIBITORS | CYP17A1, HSD17B1, CYP21A2 | CYP19A1 4/4885ALDH1A1 116/4885LMNA 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.